Approval · Notice of Compliance 35763 · 2025
LOVASTATIN: Notice of Compliance 35763
Issued July 29, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35763
- Date
- July 29, 2025
- Company
- AA Pharma Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph as per advisement letter. Product Monograph reformatted to the Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LOVASTATIN | Not yet assigned | — |
Medicinal ingredients
- LOVASTATIN 40 MG per TAB
- LOVASTATIN 20 MG per TAB